Messenger RNA delivery of a dual CD25/CD122 affinity-tuned IL-2 variant prolongs exposure and potentiates antitumor T cell immunity
Mathias Vormehr, Lena M. Kranz, Alexander Muik, Sina Fellermeier-Kopf et autres
0 citationsScience Advances
Alexander Muik
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
119Publications signalées
8852Citations signalées
1Affiliations récentes
Institutions déclarées
Domaines associés
SARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections StudiesVirus-based gene therapy researchImmunotherapy and Immune ResponsesMonoclonal and Polyclonal Antibodies Research
Publications récentes
Preclinical immunogenicity of the LP.8.1-adapted BNT162b2 COVID-19 vaccine
Chaitanya Kurhade, Wei J. Chen, Weiqiang Li, Kristin Tompkins et autres
0 citationsnpj Vaccines
Safety and Immunogenicity of BNT162b2 in Antiretroviral Therapy–Treated People With HIV
Essack Mitha, Mezgebe Berhe, Judith A. Aberg, Christopher Lucasti et autres
0 citationsOpen Forum Infectious Diseases
Lung-targeted cytokine-coding RNA-lipoplexes induce T and NK cell-mediated anti-tumor immune response
Ayline Kübler, Sophie-Christin Linkenbach, Fulvia Vascotto, Elif Diken et autres
0 citationsbioRxiv (Cold Spring Harbor Laboratory)
Strong and early immune responses against SARS-CoV-2 in mice and rhesus macaques after BNT162b3 vaccination
Annette B. Vogel, Bonny Gaby Lui, Kristin Tompkins, Isis Kanevsky et autres
0 citationsnpj Vaccines
Figure 5 from Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors
Alexander Muik, Elena Garralda, Işıl Altıntaş, Friederike Gieseke et autres
0 citations
Figure 2 from Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors
Alexander Muik, Elena Garralda, Işıl Altıntaş, Friederike Gieseke et autres
0 citations
Figure 1 from Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors
Alexander Muik, Elena Garralda, Işıl Altıntaş, Friederike Gieseke et autres
0 citations
Table 1 from Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors
Alexander Muik, Elena Garralda, Işıl Altıntaş, Friederike Gieseke et autres
0 citations
Table 2 from Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors
Alexander Muik, Elena Garralda, Işıl Altıntaş, Friederike Gieseke et autres
0 citations
Figure 3 from Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors
Alexander Muik, Elena Garralda, Işıl Altıntaş, Friederike Gieseke et autres
0 citations
Figure 4 from Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors
Alexander Muik, Elena Garralda, Işıl Altıntaş, Friederike Gieseke et autres
0 citations
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.